Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25824894 | 0.84 | RXRA (0.40) | RXRAGRIN1GRIN2BEGLN2FLT1 | |
| SCHEMBL25832879 | 0.81 | RXRA (0.36) | RXRAGRIN1GRIN2BFLT1KDR | |
| SCHEMBL25825571 | 0.76 | EGLN2 (0.46) | RXRAGRIN1GRIN2BEGLN2NOTUM | |
| SCHEMBL25820290 | 0.74 | RXRA (0.42) | RXRAGRIN1GRIN2B | |
| SCHEMBL25820296 | 0.73 | RXRA (0.58) | RXRAGRIN1GRIN2BFLT1KDR | |
| SCHEMBL13160180 | 0.71 | NOTUM (0.51) | NOTUM | |
| SCHEMBL14804465 | 0.71 | GRM5 (0.49) | — | |
| SCHEMBL13160236 | 0.71 | NOTUM (0.41) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL19105578 | 0.70 | OPRM1 (0.40) | RXRAGRIN1GRIN2BEGLN2 | |
| SCHEMBL23008630 | 0.70 | CYP1B1 (0.37) | RXRAGRIN1GRIN2BEGLN2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | RXRA 3464/4885GRIN1 1557/4885GRIN2B 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.